Cronos Group (NASDAQ:CRON – Get Free Report) and Jaguar Animal Health (NASDAQ:JAGX – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Cronos Group and Jaguar Animal Health, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cronos Group | 1 | 2 | 2 | 0 | 2.20 |
| Jaguar Animal Health | 1 | 0 | 1 | 0 | 2.00 |
Cronos Group presently has a consensus target price of $2.30, indicating a potential downside of 15.75%. Jaguar Animal Health has a consensus target price of $2,100.00, indicating a potential upside of 62,963.06%. Given Jaguar Animal Health’s higher probable upside, analysts clearly believe Jaguar Animal Health is more favorable than Cronos Group.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cronos Group | $146.59 million | 7.01 | -$9.45 million | ($0.01) | -273.00 |
| Jaguar Animal Health | $11.51 million | 0.11 | -$53.43 million | ($1,162.24) | 0.00 |
Cronos Group has higher revenue and earnings than Jaguar Animal Health. Cronos Group is trading at a lower price-to-earnings ratio than Jaguar Animal Health, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
8.7% of Cronos Group shares are owned by institutional investors. Comparatively, 12.0% of Jaguar Animal Health shares are owned by institutional investors. 7.8% of Cronos Group shares are owned by company insiders. Comparatively, 2.1% of Jaguar Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Cronos Group and Jaguar Animal Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cronos Group | -1.14% | -1.26% | -1.20% |
| Jaguar Animal Health | -464.20% | -1,194.94% | -114.26% |
Volatility & Risk
Cronos Group has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, Jaguar Animal Health has a beta of 0.01, indicating that its stock price is 99% less volatile than the S&P 500.
Summary
Cronos Group beats Jaguar Animal Health on 12 of the 14 factors compared between the two stocks.
About Cronos Group
Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.
About Jaguar Animal Health
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
Receive News & Ratings for Cronos Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group and related companies with MarketBeat.com's FREE daily email newsletter.
